Pradaxa Lawsuits Settles For $650 Million
Boehringer Ingelheim Settles US Pradaxa Litigation For $650 Million Boehringer Ingelheim will pay $650 million in a “comprehensive settlement” of
Read MoreFaulty Pharmaceutical Drugs Resources
Boehringer Ingelheim Settles US Pradaxa Litigation For $650 Million Boehringer Ingelheim will pay $650 million in a “comprehensive settlement” of
Read MorePradaxa (dabigatran etexilate mesylate) is a new blood thinning drug manufactured by Boehringer Ingelheim Pharmaceuticals. Pradaxa is in a class
Read More